| 000 | 01497 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250515031629.0 | ||
| 264 | 0 | _c20060803 | |
| 008 | 200608s 0 0 eng d | ||
| 022 | _a1537-6591 | ||
| 024 | 7 |
_a10.1086/505222 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aScollard, D M | |
| 245 | 0 | 0 |
_aDevelopment of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. _h[electronic resource] |
| 260 |
_bClinical infectious diseases : an official publication of the Infectious Diseases Society of America _cJul 2006 |
||
| 300 |
_ae19-22 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlucocorticoids _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 |
_aLeprostatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aLeprosy, Borderline _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aJoyce, M P | |
| 700 | 1 | _aGillis, T P | |
| 773 | 0 |
_tClinical infectious diseases : an official publication of the Infectious Diseases Society of America _gvol. 43 _gno. 2 _gp. e19-22 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1086/505222 _zAvailable from publisher's website |
| 999 |
_c16374350 _d16374350 |
||